UCLA researchers in the Department of Medicine have developed small molecule ENPP1 inhibitors and monoclonal antibodies for treating myocardial infarction and ocular calcification.
Myocardial infarction (MI) is the irreversible death of heart muscle tissue due to prolonged lack of oxygen. A common cause of MI is atherosclerosis, or narrowing of a coronary artery due to the accumulation of fatty plaque. The buildup of plaque progresses slowly over time, and remains asymptomatic until an atheroma ulcerates, leading to immediate blood clotting and obstruction of blood flow. Treatment of MI using antiplatelet anticoagulant (i.e. aspirin) and/or P2Y12 inhibitors (i.e. clopidogrel) aims to unblock blood vessels, reduce the clot size, and prevent clot enlargement for future MIs.
Pseudoxanthoma elasticum (Groenblad syndrome) (PXE) is a hereditary disorder that causes mineralization and calcification in elastic fibers in the skin, eyes and blood vessels. It is an orphan disease that, in the eye, leads to retinal damage and blindness. PXE can occur in young and elderly individuals.
Researchers at UCLA have observed that ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1)is highly expressed by cardiac fibroblasts in the myocardial injury site. During injury, ENPP1 is upregulated in these cardiac fibroblasts and leads to disrupted wound healing. The developed small molecule inhibitors and monoclonal antibodies antibody targeting the catalytic domain of ENPP1 prevent this disruption and present new therapeutic strategies for the preservation of cardiac function after MI.
In addition, the monoclonal antibodies can be used to screen for PXE. UCLA researchers have identified drugs in clinical use that are not known to inhibit ENPP1 or prevent ectopic calcification. These commercially used FDA approved prescription drugs and the can decrease ectopic calcification, coupled with the use of ENPP1 inhibitors, can prevent calcification and blindness.
The invention is currently at pre-clinical stage.
|United States Of America||Published Application||2022-007990||03/17/2022||2019-500|
|United States Of America||Published Application||2022-007989||03/17/2022||2019-525|
myocardial infarction, small molecule inhibitor, ENPP1, atherosclerosis